Late-Breaking Clinical Trials

Updated:Nov 3,2015
Scientific Sessions 2015 - November 7-11, 2015

Become a Member

Join or renew your membership today to save on registration for all AHA Scientific Sessions.

Late Breaking Clinical Trial Submission is closed.

Registration Information

Registration will open in June 2016.

Late-Breaking Clinical Trials

Late-Breaking Clinical Trials sessions are innovative, provide the latest breakthroughs in clinical science and potentially will have a significant impact on clinical practice. Clinical Science Report sessions will highlight trial updates, registries and important clinical science.

Failure is Not an Option: New Drugs and Systems of Care

November 8, 2015, 3:45 pm

  • A Randomized Trial of Liraglutide for High-Risk Heart Failure Patients With Reduced Ejection Fraction
  • Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction (NEAT-HFpEF
  • Oral sGC Stimulator Vericiguat in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction - The SOluble guanylate Cyclase stimulatoR in heArT failurE patientS With REDUCED EF (SOCRATES-REDUCED) Study
  • Remote Patient Management After Discharge of Hospitalized Heart Failure Patients: The Better Effectiveness After Transition - Heart Failure Study

Decreasing the Global Burden of Disease: Breakthroughs in Prevention

November 9, 2015, 10:45 am

  • The Efficacy and Safety of Varenicline, a Selective Alpha4beta2 Nicotinic Receptor Partial Agonist, for Smoking Cessation in Patients Hospitalized With Acute Coronary Syndrome: A Randomized Controlled Trial
  • Impact of a Comprehensive Lifestyle Peer-group-based Intervention on Cardiovascular Risk Factors: A Randomized Controlled Trial
  • Clinical Trial of a Mobile Health Intervention for Simultaneous versus Sequential Diet and Activity Change
  • The Effect of Disclosing Genomic Risk of Coronary Heart Disease on Low-density Lipoprotein Cholesterol Levels: The Myocardial Infarction Genes (MI-GENES) Study
  • Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

Two-Year Clinical Update: CT Surgery Network Severe MR Trial

November 9, 2015, 1:30 pm

  • Two-Year Outcomes following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

SPRINT Trial Results: Latest News in Hypertension Management

November 9, 2015, 2:00 pm
  • Systolic Blood Pressure Intervention Trial (SPRINT)
ACS and PCI: The Continuum of Care

November 10, 2015, 10:45 am

  • Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT-4)
  • Clinical Outcomes of Intravascular Ultrasound Guided Everolimus-Eluting Stents Implantation in Long Coronary Lesions
  • Long-Term Tolerability of Ticagrelor in the PEGASUS-TIMI 54 Trial
  • Individualizing Treatment Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: An Analysis of the DAPT Study
  • Angina and Quality of Life Following PCI With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial

Novel Therapies for Common Problems

November 11, 2015, 10:45 am

  • One Year Follow-up Results From AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation With Algisyl-LVR in the Treatment of Heart Failure
  • The-First-in-Man Randomized Trial of a β3-adrenoceptor Agonist in Chronic Heart Failure - the BEAT-HF Trial
  • Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Primary Results of a Randomized, 2 x 2 Factorial, Placebo-Controlled, Double-Blind Clinical Trial
  • ANNEXA™-R Part 2: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Sustained Reversal of Rivaroxaban-Induced Anticoagulation in Older Subjects by Andexanet Alfa (PRT064445), a Universal Antidote for Factor XA (FXA) Inhibitors
  • Prevention of Acute Kidney Injury by Nitric Oxide During and After Prolonged Cardiopulmonary Bypass. A Double Blind Randomized Controlled Trial
  • A Randomized, Placebo Controlled Trial of Late Na Channel Inhibition (ranolazine) in Coronary Microvascular Dysfunction (CMD): Impact on Angina and Myocardial Ischemia
  • ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 With Potential for Effective Quarterly or Possibly Bi-Annual Dosing: Results of Single-Blind, Placebo-Controlled, Phase 1 Single-Ascending Dose (SAD), and Multi-Dose (MD) Trial in Adults With Elevated LDL-C, on and off Statins


Clinical Science Special Report Sessions

Novel Findings from Next Generation Registries

November 9, 2015, 9:00 am
  • Increased Incidence of Infective Endocarditis After the 2009 European Society of Cardiology Guideline Update: A Nation-wide Study in the Netherlands
  • Examining Prevailing Genotype-Phenotype Correlations in Hypertrophic Cardiomyopathy: Findings From The Sarcomeric Human Cardiomyopathy Registry (SHaRe)
  • Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention – Findings From the NCDR-CathPCI Registry
  • Clopidogrel on Top of Aspirin for the Prevention of New-onset Migraine Headache Attacks Following Transcatheter Closure of Atrial Septal Defects: A Prospective, Randomized, Double Blind Trial (CANOA)

Cutting Edge Technologies in EP

November 9, 2015, 3:45 pm

  • Cardiac Resynchronization Therapy is Detrimental in Patients With QRS Duration Greater Than 180ms and Right Bundle Branch Block Morphology: Analysis From the Medicare ICD Registry
  • Miniaturized Transcatheter Delivered Cardiac Pacing: Primary Results of a Worldwide Clinical Trial
  • A Randomized Controlled Trial of a Video Decision Support Tool to Depict Goals of Care and Resuscitation Options for Patients With Advanced Heart Failure
  • Peri-procedural Safety of Left Atrial Appendage Occlusion With the WATCHMAN Device. Preliminary Data From the EWOLUTION Registry

Managing Risk Factors for CAD—Clinical Trial Updates

November 10, 2015, 3:45 pm

  • Cholesterol Treatment Targets and Clinical Outcomes: A JUPITER Trial Update
  • Relationship Between High-Density Lipoprotein Cholesterol and Cardiovascular and Non-Cardiovascular Mortality: A Population-Based Study of More than 630,000 Individuals Without Prior Cardiovascular Conditions in Ontario, Canada
  • Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: the Action to Control Cardiovascular Risk in Diabetes Follow-On Blood Pressure Study
  • Revascularization in Patients With Diabetes and Multivessel Coronary Artery Disease: A Population Based Evaluation of Outcomes

Submission Guidelines